1. Search Result
Search Result
Results for "

benzimidazole

" in MCE Product Catalog:

34

Inhibitors & Agonists

10

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-133694
    2-Aminoflubendazole

    Drug Metabolite Others
    2-Aminoflubendazole is the metabolite of Benzimidazoles. Benzimidazoles (BZ) are a class of drugs with activities against fungi, protozoa, and helminthes.
  • HY-W011239
    Fenbendazole sulfone

    Oxfendazole sulfone; FBZ-SO2

    Parasite Infection
    Fenbendazole sulfone (Oxfendazole sulfone;FBZ-SO2) is a minor metabolite of Fenbendazole in plasma and is a benzimidazole anthelmintic agent.
  • HY-112191
    PI3K-IN-10

    PI3K Cancer
    PI3K-IN-10 is a potent pan-PI3K inhibitor as a benzimidazole derivative, compound 332, extracted from patent WO2018057808A1.
  • HY-108411
    Emedastine

    Histamine Receptor Inflammation/Immunology
    Emedastine is an orally active, selective and high affinity histamine H1 receptor antagonist with a Ki value of 1.3 nM. Emedastine is a benzimidazole derivative with potent antiallergic properties and used for allergic rhinitis, allergic skin diseases and allergic conjunctivitis.
  • HY-B2178
    Emedastine difumarate

    Histamine Receptor Inflammation/Immunology
    Emedastine difumarate is an orally active, selective and high affinity histamine H1 receptor antagonist with a Ki value of 1.3 nM. Emedastine difumarate is a benzimidazole derivative with potent antiallergic properties and used for allergic rhinitis, allergic skin diseases and allergic conjunctivitis.
  • HY-13582
    Carbendazim

    Fungal Infection Cancer
    Carbendazim is a potent and orally active broad-spectrum benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as SeproriaFusarium and Sclerotina. Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma.
  • HY-B0263
    Thiabendazole

    2-(4-Thiazolyl)benzimidazole

    Mitochondrial Metabolism Parasite Infection
    Thiabendazole inhibites the mitochondrial helminth-specific enzyme, fumarate reductase, with anthelminthic property.
  • HY-W042648
    4,5,6,7-Tetrabromo-1H-benzimidazole

    Casein Kinase Others
    4,5,6,7-Tetrabromobenzimidazole is a selective and ATP competitive CK2 (casein kinase 2) inhibitor.
  • HY-123305
    5-Hydroxymebendazole

    Others Others
    5-Hydroxymebendazole is the one metabolite of Benzimidazoles. Benzimidazoles are safe, broad-spectrum anthelmintic drugs and are widely used for prevention and treatment of parasitic infections in food-producing animals.
  • HY-B0413
    Fenbendazole

    Parasite Antibiotic Infection
    Fenbendazole is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites.
  • HY-B0291
    Oxfendazole

    Parasite Infection
    Oxfendazole is the sulfoxide form of fenbendazole which is a broad spectrum benzimidazole anthelmintic.
  • HY-114750
    Mebendazole-amine

    Drug Metabolite Others
    Mebendazole-amine is a metabolite of Mebendazole. Mebendazole is a broad-spectrum benzimidazole anti-helminthic drug.
  • HY-B0621
    Triclabendazole

    CGA89317

    Microtubule/Tubulin Parasite Infection
    Triclabendazole(CGA89317) is a benzimidazole, it binds to tubulin impairing intracellular transport mechanisms and interferes with protein synthesis.
  • HY-103020
    BAY-1816032

    Others Cancer
    BAY-1816032 is a potent and oral available BUB1 (budding uninhibited by benzimidazoles 1) kinase inhibitor with an IC50 of 7 nM.
  • HY-13582S
    Carbendazim-d4

    Fungal Infection Cancer
    Carbendazim-d4 is the deuterium labeled Carbendazim. Carbendazim is a potent and orally active broad-spectrum benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as SeproriaFusarium and Sclerotina. Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma.
  • HY-136384
    Diethofencarb

    Fungal Infection
    Diethofencarb is a fungicide with strong activity against Botrytis cinerea and Benzimidazole-resistant strains of Botryis spp. Diethofencarb has a role as an antifungal agrochemical.
  • HY-B0223S
    Albendazole-d3

    Parasite Infection
    Albendazole-d3 is the deuterium labeled Albendazole, which is a member of the benzimidazole compounds used as a drug indicated for the treatment of a variety of worm infestations.
  • HY-135410
    ABZ-amine

    Amino albendazole

    Others Infection
    ABZ-amine (Amino albendazole) is an impurity of Albendazole. Albendazole is a member of the benzimidazole compounds used as a drug indicated for the treatment of a variety of worm infestations.
  • HY-B0299
    Oxibendazole

    Parasite Apoptosis Infection
    Oxibendazole is an effective benzimidazole anthelmintic and is against nema-tode infections. Oxibendazole can induces apoptosis and has anti-cancer and anti-inflammation activities.
  • HY-W008378
    5-Methoxy-2-benzimidazolethiol

    Others Others
    5-Methoxy-2-benzimidazolethiol is a benzimidazole. The iodimetric determination of 5-Methoxy-2-benzimidazolethiol in alkaline media is studied.
  • HY-146010
    Carbonic anhydrase inhibitor 13

    Carbonic Anhydrase Cancer
    Carbonic anhydrase inhibitor 13 (compound 7) is a potent carbonic anhydrase (CA) inhibitor, which features 3-methylthiazolo[3,2-a]benzimidazole moiety (as a tail) connected to the zinc anchoring benzenesulfonamide moiety via ureido linker.
  • HY-Y1250S4
    Fmoc-Gly-OH-1-13C

    Fungal Infection Cancer
    Fmoc-Gly-OH-1-13C is a 13C-labeled Carbendazim. Carbendazim is a potent and orally active broad-spectrum benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria, Fusarium and Sclerotina[1][3]. Carbendazim is a
  • HY-136557
    PAD2-IN-1

    Protein Arginine Deiminase Cancer Inflammation/Immunology
    PAD2-IN-1, a benzimidazole-based derivative, is a potent and selective protein arginine deiminase 2 (PAD2) inhibitor. PAD2-IN-1 shows superior selectivity for PAD2 over PAD4 (95-fold) and PAD3 (79-fold).
  • HY-110199
    TC-I 2014

    TRP Channel Neurological Disease
    TC-I 2014 (compound 5) is a potent and orally active Benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonist, with IC50 values of 0.8 nM, 3.0 nM and 4.4 nM for canine, human and rat channels respectively. TC-I 2014 exhibits antiallodynic properties in pain models.
  • HY-132768S
    N-[2-Ethoxy-d5-1-[[2'-[(hydroxyamino)methyl][1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic Acid Methyl Ester]carbamic Acid 2-Ethylhexyl Ester

  • HY-108411S
    Emedastine-13C,d3 fumarate

    Histamine Receptor Inflammation/Immunology
    Emedastine-13C,d3 (fumarate) is the 13C- and deuterium labeled. Emedastine is an orally active, selective and high affinity histamine H1 receptor antagonist with a Ki value of 1.3 nM. Emedastine is a benzimidazole derivative with potent antiallergic properties and used for allergic rhinitis, allergic skin diseases and allergic conjunctivitis.
  • HY-17507
    Pantoprazole

    BY1023; SKF96022

    Proton Pump Autophagy Apoptosis Cancer Inflammation/Immunology
    Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142).
  • HY-B0413S
    Fenbendazole-d3

    Parasite HIF/HIF Prolyl-Hydroxylase Antibiotic Infection
    Fenbendazole-d3 is a deuterium labeled Fenbendazole. Fenbendazole is a benzimidazole anthelmintic. Fenbendazole is active against Giardia in vitro (IC50 = 0.3 μM). Fenbendazole (20 mg/kg) prevents infiltration of parasites into the brain in a rabbit model of E. cuniculi infection. Fenbendazole also activates HIF-1α and prevents oxidative stress-induced death in primary neurons in vitro.
  • HY-17507B
    Pantoprazole sodium hydrate

    BY1023 sodium hydrate; SKF96022 sodium hydrate

    Proton Pump Autophagy Apoptosis Cancer Inflammation/Immunology
    Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142).
  • HY-112769
    EX229

    AMPK Metabolic Disease
    EX229, a Benzimidazole derivative, is a potent and allosteric activator of AMP-activated protein kinase (AMPK), with Kds of 0.06 μM, 0.06 μM and 0.51 μM for α1β1γ1, α2β1γ1 and α1β2γ1 in biolayer interferometry, respectively.
  • HY-17507A
    Pantoprazole sodium

    BY1023 sodium; SKF96022 sodium

    Proton Pump Autophagy Apoptosis Cancer Inflammation/Immunology
    Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole sodium, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142).
  • HY-135906
    CK2/ERK8-IN-1

    Casein Kinase ERK Pim DYRK Apoptosis Cancer
    CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) (Ki of 0.25 µM) and ERK8 (MAPK15, ERK7) inhibitor with IC50s of 0.50 μM. CK2/ERK8-IN-1 also binds to PIM1, HIPK2 (homeodomain-interacting protein kinase 2), and DYRK1A with Kis of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. CK2/ERK8-IN-1 has pro-apoptotic efficacy.
  • HY-17507S
    Pantoprazole-d6

    BY1023-d6; SKF96022-d6

    Proton Pump Autophagy Apoptosis Cancer Inflammation/Immunology
    Pantoprazole-d6 is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142).
  • HY-17507S1
    Pantoprazole-d3

    BY1023-d3; SKF96022-d3

    Proton Pump Autophagy Apoptosis Cancer Inflammation/Immunology
    Pantoprazole-d3 is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142).